Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC – OncLive
|
Dr. Kelley Discusses Biomarkers for Immunotherapy in HCC
OncLive R. Kate Kelley, MD, associate professor, University of California, San Francisco, discusses biomarkers for immunotherapy in hepatocellular carcinoma (HCC). In the advent of immunotherapy in HCC, there has been a renewed interest in determining … |
